Table 2

Multivariate Cox regression analysis predicting lung cancer-related survival of 148 patients treated by surgery for NSCLC

VariablesNSCLC (n = 148)AC (n = 68)SCC (n = 66)
HR95% CIPHR95% CIPHR95% CIP
Age at surgery0.020.810.07
0–59 yrsRef.aRef.Ref.
60+ yrs2.421.14–5.171.150.38–3.486.601.09–39.95
Gender0.260.360.72
FemaleRef.Ref.Ref.
Male1.790.77–4.191.880.49–7.200.860.25–2.97
Smoking (pack-years)0.860.780.57
0Ref.Ref.
1–191.810.22–15.002.220.19–28.89Ref.
20–391.870.23–16.171.770.20–23.731.510.28–2.68
40+2.070.23–18.453.420.21–57.042.120.29–3.56
Tumor status<0.010.010.05
T1Ref.Ref.Ref.
T22.901.30–6.471.170.28–4.832.970.80–11.00
T310.253.53–29.7510.231.91–54.6021.533.60–128
Nodal status0.010.030.95
N0Ref.Ref.Ref.
N11.700.75–3.902.270.48–10.740.820.15–4.54
N22.661.31–5.444.831.44–16.171.250.41–3.76
Mutant exon of p53 statusb0.020.820.11
wtRef.Ref.Ref.
Exon 42.250.63–8.001.560.17–14.62.020.23–17.71
Exon 51.430.68–3.040.990.27–3.601.750.60–5.14
Exon 63.170.59–16.97 c 3.620.35–37.23
Exon 71.770.83–3.781.810.53–6.211.280.37–4.40
Exon 83.501.59–7.712.030.51–8.203.191.07–9.45
Exon 95.761.57–21.08 c c
  • a Ref., reference group.

  • b Number of patients: 6 patients, exon 4; 26 patients, exon 5; 5 patients, exon 6; 18 patients, exon 7; 22 patients, exon 8; and 3 patients, exon 9.

  • c Value not estimated because there were fewer than three patients in the category.